Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common stock Series X Preferred Stock	Common stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss	Total
Beginning balance at Dec. 31, 2021	$ 96,398	$ 13	$ 481,709	$ (455,809)	$ 0	$ 122,311
Beginning balance (in shares) at Dec. 31, 2021	31,455	13,016,955
Increase (Decrease) in Shareholders' Equity
Expense related to warrants inherited in acquisition of Quellis			1,542			1,542
Issuance of common stock and warrants pursuant to an Underwriting Agreement, net of underwriter's discount and issuance costs		$ 10	107,636			107,646
Issuance of common stock and warrants pursuant to an Underwriting Agreement, net of underwriter's discount and issuance costs (in shares)		10,445,050
Issuance of common stock for at-the-market offerings, net of issuance costs		$ 4	36,987			36,991
Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)		4,012,003
Issuance of common stock upon exericse of options		$ 1	84			85
Issuance of common stock upon exercise of options (in shares)		27,332
Stock-based compensation expense			4,554			4,554
Unrealized gain (loss) on short-term investments					(79,000)	(79)
Net Income (Loss)				(51,834)		(51,834)
Ending balance at Dec. 31, 2022	$ 96,398	$ 28	632,512	(507,643)	(79,000)	221,216
Ending balance (in shares) at Dec. 31, 2022	31,455	27,501,340
Series X redeemable convertible preferred stock
Issuance of common stock upon the conversion of preferred stock	$ (1,074)		1,074
Issuance of common stock upon the conversion of preferred stock (shares)	(348)	57,910
Increase (Decrease) in Shareholders' Equity
Issuance of common stock and warrants pursuant to an Underwriting Agreement, net of underwriter's discount and issuance costs		$ 8	59,472			59,480
Issuance of common stock and warrants pursuant to an Underwriting Agreement, net of underwriter's discount and issuance costs (in shares)		8,253,895
Issuance of common stock for at-the-market offerings, net of issuance costs		$ 5	28,493			28,498
Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)		4,738,606
Issuance of common stock upon the conversion of preferred stock	$ (1,074)		1,074
Stock-based compensation expense			6,314			6,314
Issuance of common stock upon exercise of options and warrants			420			420
Issuance of common stock upon exercise of options and warrants (in shares)		483,046
Unrealized gain (loss) on short-term investments					$ 79,000	79
Net Income (Loss)				(72,891)		(72,891)
Ending balance at Dec. 31, 2023	$ 95,324	$ 41	$ 728,285	$ (580,534)		$ 243,116
Ending balance (in shares) at Dec. 31, 2023	31,107	41,034,797